A 24-month follow-up after treatment of hallux rigidus with resection arthroplasty in combination with a resorbable polymer-based implant and platelet-rich plasma

Siclari, Alberto; Krueger, J.P.; Endres, Michaela; Boux, E.

doi:10.1016/j.fas.2017.04.007

Cited by 7 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Of the 8 studies reporting preoperative and postoperative scores by way of an unmodified AOFAS-HMI scale, 6 (75.0%) reported mean improvement in the AOFAS-HMI total score exceeding 30.2 points, with the 2 additional studies reporting mean improvements of 23.0 and 24.6, respectively. 10,15,17,20,27,45,51,55 The validated Foot Function Index (FFI), Foot and Ankle Ability Measure (FAAM), the Visual Analog Scale for Pain (Pain VAS), and the Short Form–36 Health Survey (SF-36) were the next most commonly used standardized outcome scoring measures. Of the 4 studies reporting pre and postoperative scores by one of these measures, all reported mean improvements exceeding the MCIDs for their respective scoring systems (MCIDs: FAAM-ADL, 8; FAAM-Sports, 9; Pain VAS, ≥30% difference; FFI-Total, 7).…”

Section: Resultsmentioning

confidence: 99%

“…49 Many of these studies have surfaced in the literature in recent years, as the movement toward both promoting chondrostimulation and regeneration and developing matrices to serve as functional chondral replacement has gained momentum. [18][19][20][21]27,29,55 Interestingly, studies reporting on opportunities for biopsy of autogenous interposed capsular tissue in the setting of surgery needed on the lesser rays after interposition arthroplasty have noted the appearance of a viable fibrocartilaginous flap in the first MTP joint. 2,43 Despite all of these innovative and promising efforts, only 1 of the studies included in this review evaluated autogenous and allogeneic interpositional material comparatively, noting no difference in failure rate or incidence of transfer metatarsalgia between the placement of autogenous dorsal capsule and acellular dermal matrix allograft.…”

Section: Discussionmentioning

confidence: 99%

“…23,48,60 The remaining studies reported interposition of a number of allogeneic and autogenous soft tissue types and synthetic matrices (Table 1). 2,15,16,17,20,21,27,29,55 After 2010, a trend was noted toward increased usage of interpositional substances other than autogenous first MTPJ capsule (61.5% of studies after 2010 vs 7.7% of studies up through 2010).…”

Section: Interposition Materials and Metatarsophalangeal Joint Decomprmentioning

confidence: 99%

See 2 more Smart Citations

Outcomes Following Interposition Arthroplasty of the First Metatarsophalangeal Joint for the Treatment of Hallux Rigidus: A Systematic Review

Emmons

Carreira

2019

Foot & Ankle Orthopaedics

View full text Add to dashboard Cite

Background: Interposition arthroplasty of the first MTP joint has recently experienced renewed interest as a treatment for hallux rigidus. The purpose of this study was to systematically review the rapidly expanding literature on PRO following interposition arthroplasty of the first MTP joint. Methods: PubMed Central, Embase, and the Cochrane Central Register for Controlled Trials (CENTRAL) were searched. Inclusion criteria included length of time to follow-up, number of patients, outcome measure, and use of allogeneic or autogenous soft tissue or a synthetic matrix as interposition. Results: 20 studies were included in the review, comprising 498 patients and 539 feet with mean time to follow-up of 4.5 years. The most common substance used for interposition in the included studies was autogenous first MTPJ capsular tissue, a technique reported on in 12 (60.0%) of the included articles. In studies reporting preoperative and postoperative outcomes by way of a standardized outcome scoring system, mean group improvements exceed minimal clinically important differences in the majority of studies. Eighty-five percent of the studies included in this review were of Level IV quality evidence, and of this subset of studies, 70.6% were of a retrospective nature. Progression to further surgery was observed in 3.8% of toes. The most common complication reported was transfer metatarsalgia of 1 or more lesser toes, observed in up to 57.9% of patients in one study. Conclusion: Interposition arthroplasty appears to be a viable option for the treatment of moderate to severe hallux rigidus in patients looking to salvage motion through the first metatarsophalangeal joint. A wide array of autogenous, allogeneic, and synthetic implant materials have surfaced in recent years, but long-term follow-up and prospective, comparative study designs with low risk of bias are limited.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Interposition Materials and Metatarsophalangeal Joint Decomprmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes Following Interposition Arthroplasty of the First Metatarsophalangeal Joint for the Treatment of Hallux Rigidus: A Systematic Review

Emmons

Carreira

2019

Foot & Ankle Orthopaedics

View full text Add to dashboard Cite

show abstract

“…MOCART scoring at a 4 year follow-up showed complete cartilage repair in 20 of 21 patients—demonstrating lasting improvement in PRP therapies applied by PGA-HA implants. PRP-soaked PGA-HA applied to 45 patients with hallus rigidus after 3 stage resection arthroplasty showed clinically significant AOFAS and ROM and radiographical findings showed no anomalies 2 years postoperatively [117]. BMAC delivered by PGA-HA showed clinically significant IKDC score improvement [118].…”

Section: Biomaterialsmentioning

confidence: 99%

PRP and BMAC for Musculoskeletal Conditions via Biomaterial Carriers

Yamaguchi

Shams

Silva

et al. 2019

IJMS

View full text Add to dashboard Cite

Platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) are orthobiologic therapies considered as an alternative to the current therapies for muscle, bone and cartilage. Different formulations of biomaterials have been used as carriers for PRP and BMAC in order to increase regenerative processes. The most common biomaterials utilized in conjunction with PRP and BMAC clinical trials are organic scaffolds and natural or synthetic polymers. This review will cover the combinatorial strategies of biomaterial carriers with PRP and BMAC for musculoskeletal conditions (MsCs) repair and regeneration in clinical trials. The main objective is to review the therapeutic use of PRP and BMAC as a treatment option for muscle, bone and cartilage injuries.

show abstract

“…Biodegradable polyglycolic acid (PGA) has been used as resorbable suture material since the 1970s and is therefore a well-characterized material with excellent biocompatibility. It is already successfully used in the clinic as a scaffold material in articular cartilage defect treatment in knee, talus, and metatarsophalangeal joint with good short-to midterm outcomes (Siclari, Krueger, Endres, & Boux, 2018;Dhollander et al, 2012;Patrascu, Freymann, Kaps, & Poenaru, 2010;Siclari, Mascaro, Kaps, & Boux, 2014). Moreover, due to its biodegradability and approval by the Food and Drug Administration (FDA), it is a suitable material for a meniscal implant.…”

Section: Introductionmentioning

confidence: 99%

Meniscus‐shaped cell‐free polyglycolic acid scaffold for meniscal repair in a sheep model

et al. 2019

View full text Add to dashboard Cite

Since loss of meniscus is correlated with an increasing risk for osteoarthritis, meniscal scaffolds are proposed as new strategies. Development of a suitable scaffold has to take into account differing meniscus thickness, exposure to compressive and tensile forces combined with high porosity and biocompatibility of the material. After physical testing of three flat scaffolds composed of different modified polyglycolic acid (PGA) fibers, a three‐dimensional meniscus‐shaped PGA‐hyaluronan implant was generated. Micro‐computed tomography showed 90% porosity in the outer area with 50% in the inner area of the implant. Biocompatibility and expression of meniscus typical cartilaginous genes were shown for human meniscus cells cultivated in the implant with 10% human serum or 5% platelet‐rich plasma for 14 days in vitro. The proof‐of‐concept study in sheep demonstrated proteoglycan‐ and collagen type I‐rich repair tissue formation in partial meniscectomy combined with a meniscus‐shaped PGA‐hyaluronan implant after 6 months. In contrast, the control showed nearly no repair tissue formation. Thus, meniscus‐shaped PGA‐hyaluronan implants might be a suitable therapeutic approach to support repair tissue formation in partial meniscectomy.

show abstract

A 24-month follow-up after treatment of hallux rigidus with resection arthroplasty in combination with a resorbable polymer-based implant and platelet-rich plasma

Cited by 7 publications

References 26 publications

Outcomes Following Interposition Arthroplasty of the First Metatarsophalangeal Joint for the Treatment of Hallux Rigidus: A Systematic Review

Outcomes Following Interposition Arthroplasty of the First Metatarsophalangeal Joint for the Treatment of Hallux Rigidus: A Systematic Review

PRP and BMAC for Musculoskeletal Conditions via Biomaterial Carriers

Meniscus‐shaped cell‐free polyglycolic acid scaffold for meniscal repair in a sheep model

Contact Info

Product

Resources

About